Is MLYS a good stock to buy? We came across a bullish thesis on Mineralys Therapeutics, Inc. on Valueinvestorsclub.com by conway968. In this article, we will summarize the bulls’ thesis on MLYS. Mineralys Therapeutics, Inc.'s share was trading at $25.56 as of April 29th.
[caption id="attachment_564482" align="aligncenter" width="750"]Mineralys Therapeutics (MLYS) is a late-stage biotechnology company advancing lorundrostat, a selective aldosterone synthase inhibitor, for uncontrolled and treatment-resistant hypertension, and is now...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.